BRIEF published on 11/13/2025 at 14:50, 10 months 10 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
PRESS RELEASE published on 11/13/2025 at 14:45, 10 months 10 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 11 months 13 days ago Xenetic Biosciences annonce une offre d'actions de 4,5 millions de dollars Biopharmaceutique Offre D'actions Immuno-oncologie Biosciences Xénétiques Canaccord Genuity
BRIEF published on 10/10/2025 at 15:35, 11 months 13 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 11 months 13 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 1 year 1 month ago Xenetic Biosciences publie ses résultats financiers du deuxième trimestre 2025 Résultats Financiers Biosciences Xénétiques T2 2025 Développement De La DNase I Élargissement Des Partenariats
BRIEF published on 08/13/2025 at 14:05, 1 year 1 month ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 1 year 1 month ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
BRIEF published on 07/30/2025 at 15:05, 1 year 1 month ago Xenetic Biosciences collabore avec PeriNess pour une étude sur le lymphome Immuno-oncologie Étude Clinique Thérapie À La DNase I Cellule CAR-T Lymphome À Grandes Cellules B
BRIEF published on 07/30/2025 at 15:05, 1 year 1 month ago Xenetic Biosciences Collaborates with PeriNess for Lymphoma Study Clinical Study Immuno-oncology DNase I Therapy CAR T-cell Large B Cell Lymphoma
Published on 09/23/2026 at 22:00, 7 hours 43 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 11 hours 18 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 14 hours 1 minute ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 15 hours 12 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 15 hours 13 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/24/2026 at 05:08, 35 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3G and 3H
Published on 09/24/2026 at 03:24, 2 hours 18 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Notice of Annual General Meeting
Published on 09/23/2026 at 23:00, 6 hours 43 minutes ago Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS
Published on 09/23/2026 at 23:00, 6 hours 43 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 9 hours 52 minutes ago LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:46, 9 hours 57 minutes ago SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 10 hours 29 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 10 hours 29 minutes ago Performance robuste des Investissements, poursuite du déploiement de la stratégie
